Recent Updates
Recently added Catalysts

FWY003

Phase 2

Geographic Atrophy Secondary to Age-related Macular Degeneration | Small Molecules | Ophthalmology |Novartis AG|Trials Updated: Nov 9, 2026

FWY003 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Mar 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment272

FDA Designations

No designations recorded

FWY003 clinical trials

FWY003 · 1 trial · 1 indication

Phase 2 1
NCT07441642A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationGeographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING272 Analytics
PHASE2RECRUITING
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy Secondary to Age-related Macular DegenerationUnlock trial analytics

Study Endpoints

Primary Endpoints

Change of geographic atrophy (GA) lesion area in the study eye
From Baseline to Month 18

To evaluate the dose response relationship of FWY003 on GA lesion area in the study eye in participants with GA secondary to age-related macular degeneration (AMD).

Secondary Endpoints

Number of participants with adverse events (AEs) and serious adverse events (SAEs)
From first dose (Day 1) to Month 19
Change in visual function measure by ETDRS (Regular Luminance) Best Corrected Visual Acuity (BCVA) in the study eye
Baseline through Month 18
Change in visual function measure by ETDRS Low Luminance Visual Acuity (LLVA) in the study eye
Baseline through Month 18
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
FWY003 dose level 1EXPERIMENTALParticipants will receive FWY003 dose level 1
FWY003 dose level 2EXPERIMENTALParticipants will receive FWY003 dose level 2
FWY003 dose level 3EXPERIMENTALParticipants will receive FWY003 dose level 3
PlaceboPLACEBO_COMPARATORParticipants will receive placebo

Interventions

NameTypeDescription
FWY003DRUGFWY003 arm participants will receive a specific dose of FWY003
PlaceboDRUGPlacebo arm participants will receive placebo
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites65

Inclusion Criteria: Male or female participants ≥ 50 years of age. * A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye. 1. Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), ...

Countries:United StatesArgentinaAustraliaBrazilBulgariaCanadaChinaColombiaCzechiaFranceGermanyHungaryItalyJapanPolandPuerto RicoRomaniaSpainUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 9, 2026NCT07441642lastUpdatePostDate: changed
LOWNov 9, 2026NCT07441642lastUpdatePostDate: changed
LOWOct 13, 2026NCT07441642lastUpdatePostDate: changed
LOWOct 13, 2026NCT07441642lastUpdatePostDate: changed
LOWSep 9, 2026NCT07441642lastUpdatePostDate: changed
LOWSep 9, 2026NCT07441642lastUpdatePostDate: changed
LOWAug 20, 2026NCT07441642lastUpdatePostDate: changed
LOWAug 20, 2026NCT07441642lastUpdatePostDate: changed

Frequently asked questions about FWY003

What is FWY003 used for?

FWY003 is being developed for geographic atrophy secondary to age-related macular degeneration, an advanced form of dry AMD that causes progressive loss of central vision. It is an investigational small molecule in Phase 2 testing and is not yet available as a treatment outside of clinical trials.

Who is developing FWY003?

FWY003 is being developed by Novartis AG, which trades under the ticker NVS. Novartis is sponsoring the clinical program evaluating FWY003 in geographic atrophy secondary to age-related macular degeneration, an ophthalmology indication.

What phase is FWY003 in?

FWY003 is in Phase 2 clinical development. It is an investigational small molecule and has not been approved by the FDA for any use. The Phase 2 program is currently recruiting participants with geographic atrophy secondary to age-related macular degeneration.

What clinical trial is FWY003 in?

FWY003 is being studied in NCT07441642, a Phase 2 trial comparing FWY003 with placebo in participants with geographic atrophy secondary to age-related macular degeneration. The trial is recruiting and plans to enroll 272 participants across sites in the United States, Europe, Asia, Latin America, Australia, and Canada.

How is the FWY003 trial designed?

NCT07441642 is a randomized, double-blind, placebo-controlled Phase 2 trial of FWY003 in geographic atrophy secondary to age-related macular degeneration. It plans to enroll 272 participants aged 50 years and older of all sexes, and it is currently recruiting across 19 countries and territories.